Literature DB >> 22321872

Fate of individuals with ischemic amputations in the REACH Registry: three-year cardiovascular and limb-related outcomes.

Maria Teresa B Abola1, Deepak L Bhatt, Sue Duval, Patrice P Cacoub, Iris Baumgartner, Hong Keo, Mark A Creager, Danielle M Brennan, Ph Gabriel Steg, Alan T Hirsch.   

Abstract

OBJECTIVE: To evaluate systemic and limb ischemic event rates of PAD patients with prior leg amputation and determine predictors of adverse outcomes.
METHODS: The REduction of Atherothrombosis for Continued Health (REACH) Registry provided a prospective multinational cohort of 7996 outpatients with PAD enrolled from primary medical clinics in 44 countries in 2003-2004. 1160 patients (14.5%) had a prior leg amputation at any level. Systemic (myocardial infarction [MI], stroke, cardiovascular death) and limb (angioplasty, surgery, amputation) ischemic event rates were determined in a 3-year follow-up.
RESULTS: PAD patients with leg amputations on entry had a 5-fold higher rate of a subsequent amputation (12.4% vs. 2.4%, P<.001), lower rate of peripheral angioplasty (8.3% vs. 10.7%, P = .005), and similar rates of surgical revascularization procedures compared with PAD patients without amputation. A nearly 2-fold increase in rates of cardiovascular death (14.5% vs. 7.7%, P<.001) and all-cause mortality (21.8% vs. 12.6%, P<.001) and an increase in the composite outcome of MI, stroke, cardiovascular death, or hospitalization (48.7% vs. 40.0%, P<.001) were noted. Recent (≤ 1 year) amputation was associated with higher rates of worsening PAD, subsequent lower extremity surgical revascularization procedures, re-amputation, non-fatal MI, and the composite outcome, including hospitalization. Adverse systemic and limb ischemic outcomes were similar regardless of amputation level.
CONCLUSIONS: Individuals with a history of leg amputations have markedly elevated rates of systemic and limb-related outcomes. PAD patients with recent ischemic amputation have the highest risk of adverse events. A history of "minor" ischemic amputation may confer an identical systemic risk as "major" leg amputation.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22321872     DOI: 10.1016/j.atherosclerosis.2012.01.002

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  10 in total

1.  Adherence to lipid management guidelines is associated with lower mortality and major adverse limb events in patients undergoing revascularization for chronic limb-threatening ischemia.

Authors:  Thomas F X O'Donnell; Sarah E Deery; Jeremy D Darling; Katie E Shean; Murray A Mittleman; Gabrielle N Yee; Matthew R Dernbach; Marc L Schermerhorn
Journal:  J Vasc Surg       Date:  2017-05-12       Impact factor: 4.268

2.  Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry.

Authors:  Dharam J Kumbhani; Ph Gabriel Steg; Christopher P Cannon; Kim A Eagle; Sidney C Smith; Shinya Goto; E Magnus Ohman; Yedid Elbez; Piyamitr Sritara; Iris Baumgartner; Subhash Banerjee; Mark A Creager; Deepak L Bhatt
Journal:  Eur Heart J       Date:  2014-02-28       Impact factor: 29.983

3.  Proceedings from the Society of Interventional Radiology research consensus panel on critical limb ischemia.

Authors:  Sanjay Misra; Robert Lookstein; John Rundback; Alan T Hirsch; William R Hiatt; Michael R Jaff; Christopher R White; Michael Conte; Patrick Geraghty; Manesh Patel; Kenneth Rosenfield
Journal:  J Vasc Interv Radiol       Date:  2013-04       Impact factor: 3.464

4.  Strategy of Revascularization for Critical Limb Ischemia Due to Infragenicular Lesions-Which Should Be Selected Firstly, Bypass Surgery or Endovascular Therapy?

Authors:  Takahiro Ohmine; Kazuomi Iwasa; Terutoshi Yamaoka
Journal:  Ann Vasc Dis       Date:  2015-09-11

5.  Alendronate and risk of lower limb ischemic vascular events: a population-based cohort study.

Authors:  C-K Chen; H-T Chang; H-P Chou; M-H Lee; Y-C Chen; Y-C Huang; T-J Chen; H-L Chang; C-C Shih
Journal:  Osteoporos Int       Date:  2013-08-14       Impact factor: 4.507

Review 6.  New developments in the clinical use of drug-coated balloon catheters in peripheral arterial disease.

Authors:  Jesse Naghi; Ethan A Yalvac; Ali Pourdjabbar; Lawrence Ang; John Bahadorani; Ryan R Reeves; Ehtisham Mahmud; Mitul Patel
Journal:  Med Devices (Auckl)       Date:  2016-06-28

7.  Geographic variation and risk factors for systemic and limb ischemic events in patients with symptomatic peripheral artery disease: Insights from the REACH Registry.

Authors:  Jérémie Abtan; Deepak L Bhatt; Yedid Elbez; Emmanuel Sorbets; Kim Eagle; Christopher M Reid; Iris Baumgartner; David Wu; Mary E Hanson; Hakima Hannachi; Puneet K Singhal; Philippe Gabriel Steg; Gregory Ducrocq
Journal:  Clin Cardiol       Date:  2017-05-18       Impact factor: 2.882

8.  Antithrombotic Therapy for Symptomatic Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis.

Authors:  Loes H Willems; Dominique P M S M Maas; Kees Kramers; Michel M P J Reijnen; Niels P Riksen; Hugo Ten Cate; Rozemarijn J van der Vijver-Coppen; Gert J de Borst; Barend M E Mees; Clark J Zeebregts; Gerjon Hannink; Michiel C Warlé
Journal:  Drugs       Date:  2022-08-23       Impact factor: 11.431

9.  Study protocol for a prospective, longitudinal cohort study investigating the medical and psychosocial outcomes of UK combat casualties from the Afghanistan war: the ADVANCE Study.

Authors:  Alexander N Bennett; Daniel Mark Dyball; Christopher J Boos; Nicola T Fear; Susie Schofield; Anthony M J Bull; Paul Cullinan
Journal:  BMJ Open       Date:  2020-10-30       Impact factor: 2.692

10.  Status of Diabetic Neuropathy in Korea: A National Health Insurance Service-National Sample Cohort Analysis (2006 to 2015) (Diabetes Metab J 2021;45:115-9).

Authors:  Tímea Csákvári; Diána Elmer; Lilla Horváth; Imre Boncz
Journal:  Diabetes Metab J       Date:  2021-05-25       Impact factor: 5.893

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.